Work Here?
About Sarepta
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
1980
Overview
Sarepta Therapeutics focuses on developing precision genetic medicines to treat rare diseases. It specializes in Duchenne muscular dystrophy (DMD) and is advancing gene therapies for limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth disease, MPS IIIA, and other CNS disorders. The company conducts research and development, carries therapies through clinical trials, and seeks regulatory approvals to bring treatments to patients, earning revenue from approved therapies and strategic partnerships. Its goal is to speed up drug development from lab research to patient treatment and to build the world’s largest gene therapy manufacturing capacity to meet global demand.
Simplify's Take
What believers are saying
- Q1 2026 revenue hits $731 million, beating estimates by 56%.
- $700 million notes refinanced to 2030, bolstering $954 million cash.
- $600 million credit facility funds ELEVIDYS reset and pipeline advances.
What critics are saying
- FDA denies AMONDYS 45, VYONDYS 53 conversions, slashing $228 million revenue.
- Elevidys triggers permanent FDA restrictions after liver injuries, zeroing sales.
- CEO Ingram retires end-2026, sparking talent exodus and pipeline delays.
What makes Sarepta unique
- Sarepta leads DMD with PMO therapies generating $229 million in Q1 2026.
- ELEVIDYS delivers 70-73% slower DMD progression in EMBARK Phase III trial.
- Pipeline expands to DM1, FSHD siRNA and Huntington's trials by H1 2026.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$3.1B
Above
Industry Average
Funded Over
9 Rounds
Benefits
Wellness Program
Stock Price
Company News
Sarepta Therapeutics has received FDA agreement to file supplemental applications by end of April seeking conversion of AMONDYS 45 and VYONDYS 53 from accelerated to traditional approvals, using data from the ESSENCE Phase 3 study and real-world evidence in Duchenne muscular dystrophy. The regulatory conversion could validate Sarepta's exon-skipping platform and strengthen its DMD franchise durability. However, the company faces ongoing safety concerns around its gene therapy ELEVIDYS. Sarepta is enrolling non-ambulant patients to test an enhanced immunosuppression regimen, with primary endpoints focused on acute liver injury incidence. The company's narrative projects $1.4 billion revenue and $171.6 million earnings by 2028, implying 17% annual revenue decline. Most optimistic analysts forecast $713.6 million earnings on $1.9 billion revenue by 2028.
Bavarian Nordic has announced that CEO Paul Chaplin will step down after 11 years leading the Danish vaccine specialist, marking the latest executive change in pharmaceuticals this year. Chaplin, who joined in 2014, is leaving for personal reasons as his family relocates to Australia. He will remain until year-end or until a successor is found. The move follows recent departures elsewhere. Sarepta's Doug Ingram announced his retirement last month after a decade as CEO, citing family health concerns. Sanofi revealed in February it would not renew Paul Hudson's contract after six years, with share prices falling over 20% since February 2025. Belén Garijo, currently CEO of Merck KGaA, will take over at Sanofi from 29 April.
Wells Fargo has cut its price target on Sarepta Therapeutics to $38 from $45, maintaining an Overweight rating. The firm adjusted its ELEVIDYS projections, noting the gene therapy launch reset following safety events may take longer than anticipated based on 2026 guidance. However, Wells Fargo expects positive results from the company's siRNA readout. Separately, Baird reduced its price target to $20 from $22 with a Neutral rating following Sarepta's fiscal 2025 results. The company reported full-year net product revenues of $1.864 billion, comprising $965.6 million from PMO products and $898.7 million from ELEVIDYS. Sarepta Therapeutics develops RNA-targeted therapeutics and gene therapy for rare diseases, with several approved treatments for Duchenne muscular dystrophy.
Sarepta Therapeutics CEO Douglas Ingram will retire by the end of 2026 or upon appointment of his successor, the company announced in a regulatory filing. The firm has begun searching for his replacement. Ingram's departure follows a turbulent 2025 for the biotech company. Its gene therapy Elevidys, used to treat a muscle disorder, was linked to two patient deaths, prompting the FDA to request voluntary shipment halts. The company cut 500 jobs and halted development of several gene therapies. Elevidys carries the FDA's most serious safety warning and requires stringent monitoring. Despite the setbacks, Ingram said on Wednesday the therapy is on a potential pathway for expanded use. Sarepta's shares fell 82% last year and were down 4% in after-market trading. Ingram has led the company since 2017.
Sarepta Therapeutics reported 2025 net product revenue of $1.86 billion, comprising $966 million from its PMO franchise and $899 million from ELEVIDYS. The company guided 2026 approved-therapy revenue between $1.2 billion and $1.4 billion, whilst ending 2025 with $954 million in cash. Management described 2026 as a commercial "critical reset" for ELEVIDYS following two fatal events in 2025. Clinically, EMBARK three-year data showed a statistically significant 4.39-point NSAA benefit and approximately 70–73% slowing on key functional measures. Proof-of-concept readouts for DM1 and FSHD siRNA programmes are expected by end-Q1, with a Huntington's trial to begin in H1 2026. CEO Doug Ingram announced plans to retire around end-2026, with the board conducting a comprehensive successor search.
Sarepta is Hiring for 17 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Sarepta
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
1980
Sarepta is Hiring for 17 Jobs on Simplify!
Find jobs on Simplify and start your career today